Cargando…
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy
CONTEXT: Two tyrosine kinase inhibitors (TKIs), lenvatinib and vandetanib, are often used to treat advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) and medullary thyroid cancer (MTC), respectively. Fatigue is a common adverse event during treatment with these and other TKIs...
Autores principales: | Colombo, Carla, De Leo, Simone, Di Stefano, Marta, Vannucchi, Guia, Persani, Luca, Fugazzola, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402317/ https://www.ncbi.nlm.nih.gov/pubmed/30383218 http://dx.doi.org/10.1210/jc.2018-01836 |
Ejemplares similares
-
Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency
por: Ekstrand, Elise, et al.
Publicado: (2020) -
Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm
por: Colombo, Carla, et al.
Publicado: (2023) -
Effects of the therapy shift from cortisone acetate to modified-release hydrocortisone in a group of patients with adrenal insufficiency
por: Frigerio, Sofia, et al.
Publicado: (2023) -
Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism
por: Trevisan, Matteo, et al.
Publicado: (2022) -
Poor Response to Substitution Therapy with Cortisone Acetate in Patients with
Congenital Adrenal Hyperplasia
por: Inada, Hiroshi, et al.
Publicado: (2004)